RationaleMast cell diseases include mastocytosis and mast cell activation syndromes, some of which have been shown to involve clonal defects in mast cells that result in abnormal cellular proliferation or activation. Numerous clinical studies of mastocytosis have been published, but no population based comprehensive surveys of patients in the United States (U.S.) have been identified. Few mast cell disease specialty centers exist in the U.S. and awareness of these mast cell disorders is limited among non-specialists. Accordingly, information concerning the experiences of the overall estimated population of these patients has been lacking. In order to identify the experiences and perceptions of patients with mastocytosis, mast cell activation syndrome and related disorders, The Mastocytosis Society, a U.S. based patient advocacy, research and education organization, conducted a survey of its members and other people known or suspected to be part of this patient population.MethodsA web-based survey was publicized through clinics treating such patients and the Society’s newsletter, Web site and online blogs. Both online and paper copies of the questionnaire were provided, together with required statements of consent.ResultsThe first results are presented for 420 patients. These results include demographics, diagnoses, symptoms, allergies, triggers of mast cell symptoms, and disease impact.ConclusionsPatients with mastocytosis and mast cell activation syndromes have provided clinical specialists, collaborators, and other patients with information to enable them to explore and deepen their understanding of the experiences and perceptions of people coping with these disorders. RationaleMast cell diseases include mastocytosis and mast cell activation syndromes, some of which have been shown to involve clonal defects in mast cells that result in abnormal cellular proliferation or activation. Numerous clinical studies of mastocytosis have been published, but no population based comprehensive surveys of patients in the United States (U.S.) have been identified. Few mast cell disease specialty centers exist in the U.S. and awareness of these mast cell disorders is limited among non-specialists. Accordingly, information concerning the experiences of the overall estimated population of these patients has been lacking. In order to identify the experiences and perceptions of patients with mastocytosis, mast cell activation syndrome and related disorders, The Mastocytosis Society, a U.S. based patient advocacy, research and education organization, conducted a survey of its members and other people known or suspected to be part of this patient population. Mast cell diseases include mastocytosis and mast cell activation syndromes, some of which have been shown to involve clonal defects in mast cells that result in abnormal cellular proliferation or activation. Numerous clinical studies of mastocytosis have been published, but no population based comprehensive surveys of patients in the United States (U.S.) have been identified. Few mast cell disease specialty centers exist in the U.S. and awareness of these mast cell disorders is limited among non-specialists. Accordingly, information concerning the experiences of the overall estimated population of these patients has been lacking. In order to identify the experiences and perceptions of patients with mastocytosis, mast cell activation syndrome and related disorders, The Mastocytosis Society, a U.S. based patient advocacy, research and education organization, conducted a survey of its members and other people known or suspected to be part of this patient population. MethodsA web-based survey was publicized through clinics treating such patients and the Society’s newsletter, Web site and online blogs. Both online and paper copies of the questionnaire were provided, together with required statements of consent. A web-based survey was publicized through clinics treating such patients and the Society’s newsletter, Web site and online blogs. Both online and paper copies of the questionnaire were provided, together with required statements of consent. ResultsThe first results are presented for 420 patients. These results include demographics, diagnoses, symptoms, allergies, triggers of mast cell symptoms, and disease impact. The first results are presented for 420 patients. These results include demographics, diagnoses, symptoms, allergies, triggers of mast cell symptoms, and disease impact. ConclusionsPatients with mastocytosis and mast cell activation syndromes have provided clinical specialists, collaborators, and other patients with information to enable them to explore and deepen their understanding of the experiences and perceptions of people coping with these disorders. Patients with mastocytosis and mast cell activation syndromes have provided clinical specialists, collaborators, and other patients with information to enable them to explore and deepen their understanding of the experiences and perceptions of people coping with these disorders.